Introduction: The identification of genetic anomalies within the cancerous cells today constitutes very valuable information to guide the diagnosis, the classification, the choice and the monitoring of the treatment for a growing number of cancers. Mutations in the gene RAS are found in meadows of half of the colorectal cancers and their research is therefore of paramount importance for the therapeutic care and the choice of a targeted therapy appropriate. Methods: It is a retrospective study, from records of patients followed in Medical Oncology Department, for a metastatic colorectal cancer, based on the study of bio molecular RAS status; from March 2016 to November 2017. 89 cases were collected; the parameters studied were: age, histological type, location, status NRAS, KRAS and the degree of tumor infiltration. Results: Of the 89 cases studied, the average age of discovery was 59 years old (40-77). The histological type adenocarcinoma represented 100% (n = 89) of cases. In 36.92% (n = 24) of the cases the localization was colic; 9.23% (n = 6) of cases were rectal and 3.06% (n = 2). The KRAS wild was in 51.68% (n = 46) of cases, in 19.10% (n = 17) at the level of exons 2, 3, 4 and at the level of the: codon 12 in 19.10% (n = 17), codon 13 in 17.97% (n = 16. The NRAS was wild in 46,06% (n = 41) of cases; in 17.97% (n = 16) at the level of exons 2, 3, 4 and posted in 3.37% (n = 3) of the cases, at the level of: the exon 2.4 in 2.24% (n = 2) and the exon 3 in 1.12% (n = 1).The average of the tumor infiltration was 66% (40% - 90%). The response to treatment was different (right versus left) and patients achieved treatment in more than 80% of cases. DISCUSSION: It is necessary to raise the percentage of the wild character at the beginning for the KRAS and the interest of the anti-EGFR. The development of the technique of the research of the NRAS has regained less wild suggesting that some of the non-responses to anti-EGFR are probably due to this difference in the determination of the Full RAS; deserving all the interest of the clinician in the support of adequate patients. Conclusion: The targeted therapies constitute a major evolution in digestive cancer. Before the effects very promising of these drugs, other molecules of the same therapeutic classes (anti-VEGF, anti EGFR) are in course of development and will probably to further the therapeutic effects.
Read full abstract